SLC5A2 and diabetes mellitus: Several studies suggest that novelanti-diabetic drugs such as sodium–glucose cotransporter 2 (SGLT-2) inhibitorsand glucagon-like peptide-1 (GLP1) receptor agonists (GLP1RAs) can enhancecardiovascular prognoses in patients with diabetes [31, 32, 33, 34, 35, 36, 37, 38].